Adenoid Cystic Carcinoma (ACC)

Adenoid cystic carcinoma (ACC) is an uncommon cancer that most often starts in the salivary glands. It can also begin in other glands that make mucus—such as glands in the nose, sinuses, throat, windpipe, tear glands, breast, and skin. ACC usually grows slowly, but it is tricky because it likes to grow along nerves (called perineural spread). This can cause pain or numbness even when the lump is small. Under the microscope, ACC has special patterns (cribriform, tubular, solid). It can come back years later and can spread to the lungs, bones, or liver. Early diagnosis and a mix of treatments give the best chance for control.

Adenoid cystic carcinoma (ACC) is a rare cancer that starts in “gland” tissue—most often in the salivary glands of the head and neck (for example, the parotid, submandibular, palate and other minor salivary glands). ACC usually grows slowly, but it has a strong habit of growing along nerves (called perineural invasion), which can make complete removal difficult and cause symptoms like numbness, tingling, or pain along a nerve path. Even after successful treatment, ACC can return years later or spread to distant sites (often the lungs). The main treatment is surgery to remove all visible cancer, usually followed by radiation therapy to reduce the chance of the cancer coming back in the same area. Some people with advanced or returning disease may receive targeted drugs; traditional chemotherapy helps a minority and usually for a short time. Because late recurrences are common, long-term follow-up is essential. Cancer.govPMC+1

---

Another names

Adenoid cystic carcinoma is also known as ACC. In older books it may be called cylindroma because the tumor cells form round, cylinder-like spaces. (Note: today “cylindroma” usually means a different benign skin tumor, so modern doctors prefer “ACC.”) You might also see adeno-cystic carcinoma or cribriform carcinoma of salivary gland type in some reports. When it arises outside the salivary glands, the name often adds the location—for example, ACC of the lacrimal gland, tracheal ACC, or breast ACC. Pathology reports sometimes mention MYB-rearranged carcinoma, reflecting a common gene change in this cancer.

---

Types

1) By where it starts (site of origin)

• Major salivary glands: parotid, submandibular, or sublingual glands.

• Minor salivary glands: small glands in the palate (roof of mouth), lips, cheek lining, tongue, and throat.

• Sinonasal and skull base: nasal cavity, paranasal sinuses, nasopharynx, with possible spread along nerves to the skull base.

• Airway: trachea and bronchi.

• Lacrimal gland: tear gland near the eye.

• External glands and others: breast, skin adnexal glands, and rare sites (vulva, prostate, cervix).

Why this matters: Site affects symptoms, surgical options, nerve risks, and radiation planning.

2) By how it looks under the microscope (histologic pattern)

• Cribriform pattern: “Swiss-cheese” spaces; classic ACC; usually intermediate behavior.

• Tubular pattern: small tube-like glands; often the most favorable.

• Solid pattern: sheets of tumor cells with few spaces; linked to a higher risk of spread and recurrence.

Grading (common approach):

• Grade 1: predominantly tubular/cribriform, no solid areas.

• Grade 2: cribriform with <30% solid component.

• Grade 3: ≥30% solid component.
  Higher grade often means more aggressive behavior.

3) By molecular profile (key gene changes)

• MYB-NFIB fusion (or MYB activation): very common in ACC and helps confirm the diagnosis.

• MYBL1 rearrangements: an alternative driver in some tumors.

• NOTCH pathway mutations (e.g., NOTCH1): seen in a subset and may relate to more aggressive disease.

• Other alterations: changes in chromatin-modifying genes and cell-cycle regulators occur but are less consistent.

Why this matters: Molecular findings can support diagnosis, refine prognosis, and, in select cases, guide clinical trial choices.

---

Causes

ACC’s exact cause is often unknown. Below are biological drivers and epidemiologic factors described in research. I mark the current strength of evidence as strong, moderate, or limited/uncertain to be transparent.

1. MYB-NFIB gene fusion (strong): A DNA swap joins MYB and NFIB genes. This boosts MYB activity, which drives tumor cell growth and survival.

2. MYBL1 rearrangements (strong): When MYB is not altered, MYBL1 can be rearranged and act in a similar pro-growth way.

3. NOTCH pathway activation (moderate): Mutations can switch on NOTCH signaling, which supports tumor progression and perineural invasion in some cases.

4. Chromatin remodeling gene changes (moderate): Faults in genes that package DNA (epigenetic regulators) may help tumor cells switch on cancer programs.

5. Perineural growth signaling loops (moderate): Tumor cells and nearby nerves exchange growth signals (like NGF/BDNF), promoting nerve-tracking spread.

6. Angiogenic signaling (moderate): Tumor makes factors that build new blood vessels, feeding growth and aiding spread.

7. DNA repair pathway weakness (limited/uncertain): Some tumors may have repair defects that allow mutations to accumulate.

8. Therapeutic radiation exposure years earlier (moderate): Prior head-and-neck radiation can slightly raise risk for salivary gland cancers, including ACC, after a long latency.

9. Occupational carcinogens (limited/uncertain): Long-term exposure to certain industrial dusts/solvents/metals (e.g., nickel/chromium) has been discussed for salivary cancers in general, but ACC-specific proof is limited.

10. Air pollution and environmental toxins (limited/uncertain): Chronic exposure might contribute to salivary gland cancers broadly; data for ACC alone are limited.

11. Hormonal influence (limited/uncertain): ACC can occur in both sexes and at many sites; consistent hormone links are not proven.

12. Chronic local irritation/inflammation (limited/uncertain): Ongoing irritation may create a pro-tumor environment in some tissues, but strong ACC-specific data are lacking.

13. Immune dysregulation (limited/uncertain): A weakened or altered immune system could reduce surveillance against tumor cells.

14. Aging (moderate): Risk rises with age, probably due to accumulated DNA changes and weaker repair/immune control.

15. Family history of salivary gland cancer (limited/uncertain): True hereditary ACC is rare; most cases are sporadic.

16. Dietary patterns (limited/uncertain): Diet low in fruits/vegetables or high in certain processed items has been linked to cancer in general, but ACC-specific evidence is weak.

17. Viral causes (limited/uncertain): Unlike some head-and-neck cancers, HPV or EBV are not established causes of ACC.

18. Previous chemotherapy (limited/uncertain): Some drugs are linked to secondary cancers; ACC link is not clearly proven.

19. Secondhand tobacco smoke (limited/uncertain): Tobacco is not a strong risk factor for ACC specifically, but overall carcinogenic exposure is never helpful.

20. Random DNA errors (strong concept for sporadic cancers): Many ACC cases likely arise from chance mutations during normal cell division over time.

Bottom line: Genetic fusions that activate MYB (or MYBL1) are the clearest, best-supported drivers. Most lifestyle/environment links remain uncertain for ACC specifically.

---

Symptoms

1. A slow-growing lump: The most common sign. It may be painless at first, often in the palate, parotid, or submandibular area.

2. Pain in the area of the lump: Pain can be early because ACC grows along nerves. Pain may be sharp, burning, or constant.

3. Numbness or tingling: Loss of feeling or pins-and-needles happens when the tumor tracks along sensory nerves.

4. Weakness of nearby muscles: If a facial or other motor nerve is involved, weakness, drooping, or trouble moving muscles can appear.

5. Difficulty chewing or swallowing: Tumors in the mouth or throat can make eating and swallowing hard or painful.

6. Voice changes or hoarseness: ACC in the larynx or trachea can lead to a rough voice or frequent throat clearing.

7. Nasal blockage or stuffiness: Sinonasal ACC can cause one-sided blockage that does not go away.

8. Nosebleeds (epistaxis): Fragile tumor vessels in sinonasal areas can bleed easily.

9. Ear pain or fullness: Referred pain from throat or palate tumors can feel like ear pain.

10. Tooth loosening or jaw discomfort: Tumors near the upper palate or jaw can affect teeth or cause pressure.

11. Mouth ulcers or non-healing sores: A sore that does not heal on the palate or inside the cheek could be a sign.

12. Trismus (jaw stiffness): Tumor or treatment near the chewing muscles can make opening the mouth difficult.

13. Eye symptoms (for lacrimal gland ACC): Bulging eye, double vision, or pain near the eye corner.

14. Shortness of breath or wheeze (airway ACC): Tracheal tumors may narrow the airway and cause noisy breathing.

15. Unintentional weight loss or fatigue (advanced disease): May occur with long-standing or metastatic disease.

---

Diagnostic tests

Physical Examination

1. Focused head-and-neck exam: The clinician observes the face, mouth, nose, and neck; checks asymmetry, swelling, skin changes, and nerve function. This first look guides which tests are needed.

2. Oral cavity and oropharynx inspection: Bright light and tongue depressor help the doctor see the palate, gums, tongue sides, and throat. Non-healing ulcers or firm areas raise suspicion.

3. Nasal end inspection with speculum and light: For nasal obstruction or bleeding, a gentle nasal exam looks for masses and bleeding points.

4. Neck palpation for lymph nodes: The doctor feels for enlarged, firm, or fixed nodes. ACC spreads to lymph nodes less often than some cancers, but the neck must be checked.

Manual/Bedside Procedures

5. Detailed palpation of the mass: The clinician gently presses the lump to judge size, borders, tenderness, and fixation to deep tissues—clues to invasion.

6. Cranial nerve exam: A hands-on series of checks for facial movement, sensation, tongue motion, swallowing, and shoulder strength to detect perineural spread.

7. Flexible nasoendoscopy: A thin camera is passed through the nose to view the nasal cavity, nasopharynx, and larynx. It maps visible tumor, bleeding sites, and airway narrowing.

8. In-office ultrasound (for salivary masses): A handheld probe shows if a lump is solid or cystic and can guide a needle for sampling.

Laboratory & Pathological Tests

9. Fine-needle aspiration (FNA) cytology: A thin needle collects cells from the lump. Cytology can suggest ACC and rule out other tumors, helping plan surgery or biopsy.

10. Core needle biopsy: A slightly larger needle retrieves a tissue core. It preserves architecture, which helps differentiate ACC from other salivary tumors before treatment.

11. Incisional/excisional biopsy (when needed): A small piece or the whole small lesion is removed for full histology. This provides the most reliable diagnosis.

12. Histopathology with H&E staining: The pathologist looks for cribriform/tubular/solid patterns, perineural invasion, and lymphovascular invasion—key features that define ACC.

13. Immunohistochemistry (IHC): Stains such as c-KIT (CD117), MYB protein, SOX10, and others support an ACC diagnosis and help exclude mimics.

14. Molecular testing for MYB/MYBL1 fusions: Methods like FISH, RT-PCR, or next-generation sequencing confirm gene rearrangements and can settle tough diagnostic cases.

15. Proliferation index (e.g., Ki-67): Estimates how fast the tumor cells are dividing. Higher rates can suggest a more aggressive tumor.

16. Routine blood tests (baseline labs): Blood counts, kidney/liver function help plan treatments (surgery, radiation, systemic therapy) and detect treatment risks, though they do not diagnose ACC itself.

Electrodiagnostic Tests

17. Nerve conduction studies (when nerve dysfunction is suspected): Measures how well signals travel along sensory or motor nerves near the tumor. Helps document perineural impact.

18. Electromyography (EMG): Evaluates muscle electrical activity. If facial weakness or swallowing problems are present, EMG can quantify nerve injury and recovery potential.

Imaging Tests

19. Contrast-enhanced MRI of the primary site and skull base: The best test for soft tissue and nerves. It maps tumor size, tracks perineural spread along nerve canals, and guides surgery and radiation fields.

20. CT scan (head/neck or chest, with contrast as indicated): Excellent for bone erosion and surgical planning; chest CT checks for lung spread, which is the most common metastatic site in ACC.
    Optional adjuncts: PET-CT can help in selected patients to look for distant disease; ultrasound is helpful for salivary lesions and needle guidance.

Non-pharmacological treatments

Notes: These help with function, symptoms, and recovery. They do not treat the cancer itself. Always coordinate with your oncology team.

1. Pre-habilitation exercise plan
   Builds strength and lung fitness before surgery or radiation with gentle aerobic + resistance training (e.g., walking + light bands 2–3×/week). Purpose: improve recovery, reduce fatigue. Mechanism: boosts cardiovascular capacity, preserves muscle. Benefits: fewer treatment interruptions, better energy. ASCO Publications

2. Post-treatment aerobic walking
   Purpose: rebuild stamina; Mechanism: raises mitochondrial efficiency; Benefits: lowers fatigue and improves mood during/after therapy. ASCO Publications

3. Light resistance training
   Purpose: maintain muscle and shoulder/neck strength after head-neck surgery or radiation; Mechanism: muscle protein synthesis via mechanical load; Benefits: function, posture, swallowing support. ASCO Publications

4. Neck, jaw, and shoulder range-of-motion (physiotherapy)
   Purpose: prevent stiffness, trismus, and shoulder dysfunction (especially after parotid/submandibular surgery). Mechanism: gentle stretching/mobilization; Benefits: better mouth opening, alignment, and daily activity. (Head-and-neck cancer rehab literature supports targeted physio.)

5. Swallowing therapy (speech-language pathology)
   Purpose: safer swallowing and nutrition; Mechanism: oropharyngeal muscle retraining; Benefits: reduce choking/aspiration, maintain weight.

6. Lymphedema therapy (head and neck)
   Purpose: reduce swelling and heaviness; Mechanism: specialized massage, compression, exercises; Benefits: comfort, appearance, range-of-motion.

7. Voice and speech therapy
   Purpose: optimize voice, articulation, and resonance after palate/sinus/oropharyngeal procedures; Mechanism: targeted phonation drills; Benefits: clearer speech, confidence.

8. Dental oncology care before radiation
   Purpose: lower risk of osteoradionecrosis and tooth decay; Mechanism: dental exam, extractions if needed, fluoride plan; Benefits: safer radiation course, long-term oral health.

9. Oral care protocol to prevent mucositis
   Purpose: reduce mouth sores during radiation/chemo; Mechanism: frequent bland rinses, soft brush; Honey swish-and-swallow may help prevent radiation-related mucositis in head-and-neck cancer. Benefits: less pain, better nutrition. PMCASCO Post

10. Nutrition counseling
    Purpose: maintain weight and protein while managing taste changes and dry mouth; Mechanism: energy-dense, moist, easy-to-chew meals; Benefits: fewer breaks in therapy, stronger recovery. (ASCO diet/exercise guidance discourages “neutropenic” diets in most cases.) PubMed

11. Dry-mouth (xerostomia) management
    Purpose: comfort and dental protection; Mechanism: frequent sips, saliva substitutes, sugar-free gum/xylitol; Benefits: easier eating, fewer cavities.

12. Pain self-management skills
    Purpose: reduce distress and reliance on rescue meds; Mechanism: pacing, heat/cold, relaxation; Benefits: better daily function. (SIO-ASCO integrative pain guidance supports selected complementary measures.) Oncology Nursing Society

13. Mindfulness-based stress reduction
    Purpose: lower anxiety, improve sleep; Mechanism: attention training calms sympathetic drive; Benefits: quality of life.

14. Brief cognitive behavioral therapy (CBT) for insomnia or anxiety
    Purpose: better sleep and coping; Mechanism: restructure unhelpful thoughts/behaviors; Benefits: energy, adherence.

15. Guided imagery or breathing exercises
    Purpose: quick stress relief; Mechanism: parasympathetic activation; Benefits: pain and nausea modulation.

16. Acupuncture for nausea/pain (as appropriate)
    Purpose: symptom relief; Mechanism: neuromodulation; Benefits: adjunct control of nausea and some pain syndromes; choose oncology-trained practitioners. (Integrative oncology guidance supports selected use.) integrativeonc.org

17. Massage therapy (oncology-adapted)
    Purpose: reduce muscle tension; Mechanism: mechanoreceptor stimulation; Benefits: comfort, range-of-motion.

18. Yoga/Tai Chi (gentle)
    Purpose: balance, flexibility, mood; Mechanism: combined movement + breath; Benefits: fatigue and anxiety relief. (Supported as complementary by integrative guidelines.) integrativeonc.org

19. Smoking and alcohol counseling (if relevant)
    Purpose: support healing and lower second-cancer risk; Mechanism: behavioral coaching; Benefits: wound and dental health.

20. Work and school re-entry planning (educational therapy)
    Purpose: paced return; Mechanism: graded activity plan; Benefits: sustained recovery.

21. Swallow-friendly cooking skills training
    Purpose: meet calories/protein with dry mouth or taste change; Mechanism: recipe modifications (sauces, gravies, smoothies); Benefits: easier eating.

22. Fatigue pacing & energy budgeting
    Purpose: match energy to tasks; Mechanism: schedule “rest breaks,” prioritize; Benefits: fewer crashes.

23. Support groups or peer navigation
    Purpose: practical and emotional support; Mechanism: shared experience; Benefits: adherence and coping.

24. Sun and skin care during radiation
    Purpose: protect radiated skin; Mechanism: gentle cleansers, moisturizers; Benefits: comfort.

25. Long-term survivorship plan
    Purpose: structured follow-up for late recurrences; Mechanism: scheduled visits and imaging when indicated; Benefits: early detection. PMC

Drug treatments

Important: Many systemic therapies for ACC are off-label or clinical-trial based. Doses below are typical starting points from studies/labels—your team adjusts for you.

1. Lenvatinib (VEGFR/FGFR TKI) – Common starting dose: 24 mg orally once daily. Purpose: slows tumor blood-vessel growth in recurrent/metastatic (R/M) ACC. Mechanism: blocks VEGFR1-3 and other kinases. Side effects: hypertension, fatigue, diarrhea, hand-foot syndrome; requires blood-pressure monitoring and dose adjustments. Phase II studies showed meaningful disease control and responses in some patients. ASCO PublicationsPubMed

2. Axitinib (VEGFR TKI) – Dose: 5 mg orally twice daily (titrate). Purpose: disease control in progressive R/M ACC. Mechanism: VEGFR1-3 blockade. Side effects: hypertension, diarrhea, fatigue. Randomized and single-arm phase II studies show stabilization in a subset. PubMedAACR Journals

3. Rivoceranib / Apatinib (VEGFR-2 TKI) – Dose used in trials: ~700 mg daily. Purpose: responses and disease control in R/M ACC. Mechanism: potent VEGFR-2 inhibition. Side effects: hypertension, proteinuria, hand-foot reaction. Phase II data (RM-202) support activity. PubMedAACR Journals

4. Sorafenib (multi-kinase TKI) – Dose: 400 mg twice daily. Purpose: disease stabilization in some cases. Mechanism: RAF/VEGFR/PDGFR inhibition. Side effects: hand-foot reaction, fatigue, hypertension. (Observational/early studies.) accrf.org

5. Sunitinib or Pazopanib (multi-kinase TKIs) – Dose: sunitinib 37.5–50 mg daily; pazopanib 800 mg daily. Purpose: occasional disease control. Mechanism: anti-angiogenic. Side effects: fatigue, hypertension, cytopenias; liver test monitoring required. (Small studies/series.) esmoopen.com

6. Cisplatin-based combinations (e.g., CAP: cyclophosphamide + doxorubicin + cisplatin) – Schedules vary. Purpose: short-term tumor shrinkage or symptom relief in selected R/M cases. Mechanism: cytotoxic. Side effects: nausea, myelosuppression, neuropathy, kidney injury; pre-hydration needed. Responses occur in a minority and often do not last. sborl.es

7. Carboplatin + Paclitaxel (or Docetaxel) – Purpose: palliative option when rapid control is needed. Mechanism: cytotoxic. Side effects: neuropathy, low counts, fatigue. (Evidence limited; individualized.) esmoopen.com

8. Immunotherapy (PD-1/PD-L1 inhibitors such as pembrolizumab, nivolumab, avelumab) – Purpose: selected patients, often within trials; single-agent activity in ACC is modest. Side effects: immune-related events (thyroiditis, pneumonitis). Combination with anti-VEGFR agents (e.g., axitinib + avelumab) has shown signals of activity in R/M ACC. ESMOPMC

9. NOTCH-pathway inhibitors (investigational) – Purpose: for tumors with activating NOTCH1 mutations (linked to more aggressive behavior). Mechanism: gamma-secretase/NOTCH blockade; access mainly via trials. Side effects: diarrhea, rash, fatigue. (Prognostic importance of NOTCH1 is supported; targeted therapy remains experimental.) oooojournal.net

10. HRAS-targeted therapy (tipifarnib) in HRAS-mutant tumors (rare in ACC) – Purpose: mutation-selected therapy; Mechanism: farnesyltransferase inhibition; Note: case-by-case or trial setting. (Mutation-directed approaches are emerging.) esmoopen.com

11. EGFR-targeted agents (cetuximab/erlotinib; limited role) – Purpose: occasional palliation; Mechanism: EGFR blockade; Note: evidence in ACC is weak; consider only with specialist input/trials. esmoopen.com

12. Androgen-pathway therapies (rare ACC subsets) – Purpose: select AR-expressing tumors; Note: uncommon in ACC; evidence sparse. (Specialist-guided.) esmoopen.com

13. HDAC inhibitors (e.g., vorinostat) in trials/combos – Purpose: epigenetic modulation (investigational). Note: small signals; toxicity monitoring. PMC

14. Supportive hematologic agents (filgrastim/pegfilgrastim, ESAs per criteria) – Purpose: manage chemo-related low counts, reduce treatment delays; Mechanism: stimulates bone marrow. Note: used only when indicated. (Supportive-care standards.) PubMed

15. Analgesics and neuropathic-pain agents (e.g., acetaminophen, cautious NSAIDs if safe, gabapentin, duloxetine) – Purpose: nerve-pain and post-treatment pain relief; Mechanism: central/peripheral modulation; Note: avoid interactions with TKIs; coordinate with oncology/pharmacy. (General supportive-care practice.) Oncology Nursing Society

Dietary molecular/supportive supplements

Strong caution: supplements can interact with TKIs and chemo (for example, St. John’s wort lowers TKI levels). Always clear any supplement with your oncology pharmacist.

1. High-protein oral nutrition (whey/pea blends) – helps meet protein targets for healing; mechanism: amino acids for tissue repair; typical use: 20–30 g protein shakes between meals.

2. Omega-3 fatty acids (fish oil/ALA foods) – may support weight maintenance and reduce inflammation; common dose: 1–2 g/day EPA+DHA with food (if not on anticoagulants).

3. Vitamin D (if deficient) – supports bone/immune health; dose per blood test (often 800–2000 IU/day maintenance).

4. Calcium (diet first; supplement if needed) – dental/bone support; dose individualized (total ~1000–1200 mg/day from food + pills).

5. Vitamin B12/folate (if low) – supports blood counts and nerve health; dose guided by labs.

6. Zinc (short-term for taste changes if deficient) – may help dysgeusia; typical short courses only to avoid copper deficiency.

7. Selenium (only if deficient) – antioxidant support; lab-guided.

8. Probiotics (select strains) – may help bowel regularity during therapy; avoid during severe neutropenia; choose medically reviewed products.

9. Medical-grade honey for mucositis prevention – topical swish-and-swallow around radiation sessions; mechanism: anti-inflammatory and barrier effects; evidence suggests benefit in head-and-neck therapy. PMCASCO Post

10. Glutamine (for mouth/throat discomfort—mixed data) – discuss with team; dosing and benefit vary; avoid if contraindicated. PMC

Immunity-booster / regenerative / stem-cell drugs

There are no proven “stem-cell drugs” or over-the-counter “immunity boosters” that treat ACC. Unregulated “regenerative” products can be harmful or interfere with your cancer therapy. When doctors support the blood system during chemo, they use approved growth factors (e.g., filgrastim/pegfilgrastim for white cells; ESAs in select anemia cases) following strict criteria—not to treat the cancer, but to keep treatment safe. For immune protection, clinicians use vaccines (e.g., influenza, COVID-19 as advised) and infection-prevention steps, not alternative “boosters.” I can’t recommend stem-cell or “regenerative” drugs for ACC outside clinical trials; instead, your team may use the supportive agents listed above when medically indicated. PubMed

Surgeries

1. Parotidectomy (superficial or total) with nerve management
   Procedure: remove tumor in the parotid gland; preserve or reconstruct facial nerve if safe. Why: clear margins are the best chance for control. Adjuvant radiation is common if margins are close/positive or there is perineural invasion. Cancer.gov

2. Submandibular gland excision ± neck dissection
   Procedure: remove affected gland; selective neck dissection only if nodes are involved or for access. Why: achieve complete removal; nodes are less often positive in ACC than in other head-neck cancers. Cancer.gov

3. Palate/maxillary resection (for minor salivary ACC)
   Procedure: remove tumor with clear bone/soft-tissue margins; prosthetic obturator or reconstruction as needed. Why: local control and function.

4. Skull-base/perineural tract resection when feasible
   Procedure: carefully follow named nerve pathways to the skull base; often combined with advanced radiation. Why: ACC often spreads along nerves. Red Journal

5. Organ-specific resections (e.g., tracheal, sinonasal) in specialized centers
   Procedure: segmental resections with reconstruction. Why: disease control with acceptable function when anatomically possible.

6. Adjuvant IMRT or proton therapy after surgery lowers local-recurrence risk, especially with close/positive margins or perineural invasion. Proton therapy can help spare nearby critical structures (e.g., skull base, orbit) while delivering high tumor doses. Lippincott JournalsScienceDirect

7. Fast-neutron therapy has shown superior local control in unresectable or gross-residual salivary cancers at select centers; access is limited, and modern proton/carbon-ion options are also used in specialized programs. PubMed

Prevention

ACC has no proven lifestyle prevention. Still, you can lower overall cancer and treatment-risk burdens by:

1. not smoking; 2) moderating alcohol; 3) using dental care and daily fluoride if radiated; 4) vaccinations (flu/COVID-19 per guidance); 5) exercise and healthy weight; 6) workplace safety (avoid unnecessary radiation/chemical exposures); 7) prompt evaluation of persistent salivary swellings, nerve pain, or numbness; 8) nutrition that maintains strength; 9) sun/skin care in treated areas; 10) long-term follow-up to catch late recurrences early. ASCO Publications

When to see doctors urgently

• New or worsening numbness, tingling, or pain tracing a nerve path in the face, jaw, tongue, palate, or ear.

• A new lump in salivary areas or neck that lasts >3 weeks.

• Difficulty swallowing, voice change, or jaw opening problems.

• Weight loss, persistent cough, or breathlessness (possible lung spread).

• Mouth sores so painful you can’t eat or drink, or any fever during treatment. (These need rapid assessment.) Cancer.gov

What to eat and what to avoid

Eat more: soft, moist, high-protein foods (eggs, yogurt, tofu, fish, beans), smoothies with protein powder, ripe fruits, cooked vegetables with olive oil, soups, oatmeal, and plenty of fluids. Flavor tips: marinades, herbs, tart flavors, and gravies help with dry mouth and taste changes.
Limit/avoid: very dry, sharp, or spicy foods if they hurt; alcohol and tobacco; high-dose herbal products that interact with cancer medicines (especially St. John’s wort with TKIs). A “neutropenic diet” is not routinely recommended for most people in treatment. PubMed

FAQs

1. Is ACC curable?
   Often yes when small and fully removed, especially with adjuvant radiation; however, ACC can recur years later, so follow-up is long-term. Cancer.govPMC

2. Why do doctors worry about “perineural invasion”?
   ACC travels along nerves; this raises the risk of local recurrence and guides wider surgery and radiation fields. Cancer.gov

3. Where does ACC spread?
   Most often the lungs; less often bone or liver. PMC

4. Is chemotherapy effective?
   It can help some people for a time, but responses are usually modest and temporary; today, anti-angiogenic TKIs (e.g., lenvatinib, rivoceranib, axitinib) are commonly considered for progressive metastatic disease. PubMed+2PubMed+2

5. Does immunotherapy work?
   Single-agent PD-1/PD-L1 drugs have limited benefit in ACC; combination strategies (e.g., VEGFR TKI + immunotherapy) are under study. ESMOPMC

6. What about proton or neutron radiation?
   For complex skull-base/perineural disease, protons can deliver high doses while sparing normal tissue. Fast-neutron therapy has shown strong local control in unresectable/gross-residual salivary tumors but is available at few centers; specialized referral is needed. Lippincott JournalsPubMed

7. Which imaging is best to map nerve spread?
   MRI with contrast along cranial-nerve pathways; PET-CT is often added for whole-body staging. PMC+1

8. What genes are important in ACC?
   MYB/MYBL1 rearrangements are common; NOTCH1 mutations define a more aggressive subset and may guide trial enrollment. PNASoooojournal.net

9. How long should I be followed after treatment?
   For life, with closer visits early on and spaced out later—because late recurrences are well documented. PMC

10. Can diet or supplements cure ACC?
    No. Nutrition supports strength and healing but does not cure cancer. Avoid supplement-drug interactions. PubMed

11. What if my tumor grows slowly—do I need treatment now?
    Sometimes doctors watch indolent metastatic disease closely and start systemic therapy only when it clearly progresses or causes symptoms. This is individualized. ASCO Publications

12. Are clinical trials important in ACC?
    Yes—ACC is rare, and trials offer access to promising targeted or combination treatments. Ask your team about trials that match your tumor features. ASCO Publications

13. Will I lose my facial nerve if I have parotid ACC?
    Surgeons aim to preserve it if margins and safety allow; if involved by tumor, segments may need resection with reconstruction, plus postoperative radiation. Cancer.gov

14. What can I do to get through radiation better?
    Follow oral-care plans, keep calories/protein up, consider medical-grade honey for mucositis prevention (ask your team), and keep moving daily. PMC

15. What specialists should be on my team?
    Head-and-neck surgical oncologist, radiation oncologist (with proton/neutron access if needed), medical oncologist, dental oncologist, speech/swallow therapist, dietitian, physical therapist, and psychosocial support. ASCO/ESMO/NCI guidance all emphasize multidisciplinary care. ASCO Publicationsesmoopen.com

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 08, 2025.